NR3C2 and Hyperkalemia: Hyperkalemia is also a common adverse event associated with RAS inhibitors [35–37], and the addition of a steroidal MR blocker to an RAS inhibitor can significantly increase the risk of hyperkalemia (P < 0.00001) [38].